• Eli Lilly (NYSE: LLY) has entered a new clinical trial collaboration with Amplia Therapeutics to test a novel drug combination in non-small cell lung cancer.
• The move extends Eli Lilly's precision oncology efforts following Breakthrough Therapy designation for its KRAS G12C inhibitor in a rare pancreatic cancer subset.
• Eli Lilly also joined Remedium Bio's Series A financing, adding exposure to early-stage durable protein therapeutics beyond its existing metabolic disease portfolio.

This focus on oncology and next-generation therapeutics is shared by many other publicly traded drug developers that you can review through 19 top founder-led companies

Eli Lilly sits among the larger global pharmaceutical companies by market value, and the current share price of $1,231.94 reflects strong recent trading momentum. The stock has returned 14.0% year to date and 95.3% over the past year, with gains of 133.4% over three years and 376.9% over five years, which keeps investor attention firmly on how new partnerships may influence future expectations.

What actually changed for Eli Lilly with this oncology news?

Eli Lilly is tying its strong Q2 2026 financial performance more closely to its pipeline and partnership strategy. On top of quarterly sales of US$22.97b and net income of US$7.10b, the company raised 2026 revenue guidance to US$85b to US$87b. The new Amplia Therapeutics trial collaboration around olomorasib in KRAS G12C non small cell lung cancer, plus Breakthrough Therapy designation in KRAS G12C pancreatic cancer and participation in Remedium Bio’s Series A, show Lilly using that earnings base to extend reach into precision oncology and durable protein therapeutics.

Does this change the Eli Lilly Narrative around GLP 1 dependence?

The Narrative on Eli Lilly has been dominated by incretin drugs like Mounjaro and Zepbound, which underpin recent revenue and earnings trends. These oncology partnerships and the FDA designation for olomorasib add more weight to the idea that Lilly is building additional pillars outside diabetes and obesity. However, they are still at trial and early funding stages, so for now they complement rather than replace the current reliance on GLP 1 driven cash flows that sit behind the raised 2026 guidance.

What is the one thing to watch next after Eli Lilly’s oncology moves?

The key signpost is concrete progress in olomorasib’s clinical and regulatory path. Watch for the start of the Amplia Phase 1b/2b combination study in late 2026 and any updated readouts from the LOXO RAS 20001 trial, particularly around safety and efficacy in KRAS G12C pancreatic and lung cancer. Evidence that these programs are moving toward registrational studies would support the view that Lilly’s oncology strategy can meaningfully complement its existing earnings base.

For the full picture including more risks and rewards, check out the complete Eli Lilly analysis. Alternatively, you can check out the community page for Eli Lilly to see how other investors believe this latest news will impact the company's narrative.

Do you think there's more to the story for Eli Lilly? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.